Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTH
Nasdaq
2833
https://www.cyclotherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cyclo Therapeutics Inc
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
- May 18th, 2022 12:00 pm
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
- May 12th, 2022 8:05 pm
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
- May 9th, 2022 12:05 pm
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
- Mar 29th, 2022 12:35 pm
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
- Mar 24th, 2022 12:05 pm
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
- Mar 23rd, 2022 12:25 pm
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
- Mar 14th, 2022 12:05 pm
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
- Mar 10th, 2022 1:05 pm
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
- Feb 8th, 2022 1:05 pm
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
- Feb 3rd, 2022 1:05 pm
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
- Jan 20th, 2022 1:05 pm
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Jan 12th, 2022 3:35 pm
Here's Why Cyclo Therapeutics (NASDAQ:CYTH) Must Use Its Cash Wisely
- Dec 16th, 2021 11:16 am
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
- Dec 9th, 2021 1:05 pm
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
- Dec 6th, 2021 1:05 pm
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
- Nov 17th, 2021 1:28 am
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
- Nov 16th, 2021 9:27 pm
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
- Nov 16th, 2021 1:05 pm
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
- Nov 15th, 2021 9:20 pm
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
- Nov 10th, 2021 1:05 pm
Scroll